EGCG was initially tested in DS because of its properties as inhibitor of the kinase encoded by the Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (DYRK1A), a DS candidate gene located in the 21q22.2 human chromosome region (Duchon and Herault, 2016). This evidence concerns the gene DYRK1A and Dravet syndrome.